순환종양세포 시장 보고서 : 기술, 용도, 제품, 검체, 최종사용자, 지역별(2026-2034년)

The global circulating tumor cells (CTC) market size reached USD 14.0 Billion in 2025. Looking forward, IMARC Group expects the market to reach USD 28.0 Billion by 2034, exhibiting a growth rate (CAGR) of 7.80% during 2026-2034. North America dominates the market, driven by advancements in technologies and increasing investments in research and development (R&D) activities. Hospitals are implementing liquid biopsy techniques, such as CTC analysis, because of their low invasiveness. The high occurrence of genetic disorders, due to lifestyle alterations, is fueling the market share.

CIRCULATING TUMOR CELLS (CTC) MARKET ANALYSIS:

• Major Market Drivers: The inflating need for real-time monitoring and early identification of breast, lung, digestive tract, and prostate cancer is bolstering the market.
• Key Market Trends: The widespread adoption of minimally invasive (MI) diagnostic procedures is acting as a significant growth-inducing factor.
• Competitive Landscape: Some of the prominent companies in the market include BioFluidica, Bio-Techne, Cell Microsystems, Creatv MicroTech Inc., CytoLumina, Ikonisys Inc., Menarini Silicon Biosystems Inc., Miltenyi Biotec, Precision Medicine Group, LLC, Qiagen N.V., Rarecells, Inc., Stemcell Technologies, and Thermo Fisher Scientific Inc., among many others.
• Geographical Trends: The rising investments in medical research to develop cell culture models for disease modeling, genome editing, drug screening, and tumor immunity are contributing to the market in North America.
• Challenges and Opportunities: The high complexity of analysis technologies is hindering the market. However, the development of more affordable, simplified, and high-throughput methods for CTC isolation is expected to fuel the market over the forecasted period.

CIRCULATING TUMOR CELLS (CTC) MARKET TRENDS:

Rising global cancer prevalence

Increasing global cancer prevalence is fueling the market expansion, as the growing number of cancer cases is demanding more efficient and less invasive diagnostic solutions. As per the Indian Council of Medical Research, a projected 12.8% rise in cancer cases is anticipated by 2025 in comparison to 2020. With millions of new cases documented each year, healthcare systems are facing pressure to implement inventive strategies for early detection, monitoring, and treatment direction. CTCs offer important information on tumor development and metastasis without needing repeated invasive biopsies, thus becoming a favored choice for oncologists. The increasing prevalence of aggressive cancers like breast, prostate, and lung cancer is further driving the need for diagnostics based on CTCs. With patients and clinicians pursuing real-time tracking, the importance of CTCs is growing significantly.

Growth of precision medicine and personalized therapies

The growth of precision medicine and personalized therapies is making cancer care more targeted and effective. As per the IMARC Group, the global precision medicine market size reached USD 82.1 Billion in 2024. CTCs enable real-time analysis of tumor biology, helping clinicians tailor treatments based on individual patient profiles rather than generic approaches. This supports the growing shift towards therapies that maximize efficacy while minimizing side effects. By identifying specific genetic mutations, drug resistance patterns, and tumor progression, CTC analysis enhances the success rate of personalized therapies. Pharmaceutical companies are also using CTCs in clinical trials to evaluate treatment responses, accelerating drug development pipelines. As precision medicine is gaining momentum worldwide, the demand for CTC-based diagnostics and monitoring is expanding, making them an integral component of next-generation cancer management strategies.

Increasing awareness about liquid biopsy

Rising awareness about liquid biopsy is offering a favorable market outlook, as both patients and healthcare providers are recognizing its benefits over traditional tissue biopsies. Hospitals are adopting liquid biopsy methods, including CTC analysis, due to their minimally invasive nature, faster results, and ability to monitor tumor changes in real-time. In July 2025, Fortis Memorial Research Institute (FMRI) in Gurugram, collaborating with Agilus Diagnostics, launched its second Genexus system. The Genexus platform provided NGS-based tests with a quicker turnaround, such as Liquid Biopsy in 24 hours, Myeloid NGS in 72 hours, and minimal residual disease (MRD) testing in five days. Unlike surgical biopsies, liquid biopsies can be performed more frequently, allowing continuous assessment of treatment effectiveness and early detection of resistance. Awareness campaigns by healthcare organizations, combined with scientific advancements, are also encouraging adoption in oncology departments.

KEY GROWTH DRIVERS OF CIRCULATING TUMOR CELLS (CTC) MARKET:

Advancements in CTC isolation and detection technologies

Advancements in CTC isolation and detection technologies are improving accuracy, sensitivity, and efficiency in cancer diagnostics. Traditional challenges in isolating rare CTCs from blood samples are being addressed through innovations in microfluidics, immunomagnetic separation, and nanotechnology-based platforms. These advanced methods enable better capture and analysis of CTCs, providing reliable insights into tumor biology and progression. Enhanced detection capabilities also allow monitoring minimal residual disease and identifying drug resistance, which supports personalized treatment planning. As technology is evolving, costs are gradually decreasing, making these solutions more accessible to hospitals and laboratories. With improved clinical reliability and wider adoption, technological progress is significantly fueling the growth and application scope of the CTC market.

Rising regulatory approvals for CTC-based diagnostic kits

Increasing regulatory approvals for CTC-based diagnostic kits are positively influencing the market by enhancing trust, accessibility, and clinical adoption. Regulatory bodies are granting approvals for new CTC isolation and detection systems, ensuring their safety, reliability, and clinical utility. These approvals not only validate the effectiveness of such technologies but also encourage healthcare providers to integrate them into standard cancer care practices. Moreover, regulatory clearances help companies expand globally, reaching new markets with compliant products. The availability of approved kits is also accelerating collaborations between biotech firms, hospitals, and research institutions. As more diagnostic products are gaining official authorization, the CTC market is witnessing stronger adoption, its function in the early identification, outlook, and observation of cancer patients.

Increasing government and private funding in cancer diagnostics

Rising government and private funding in cancer diagnostics is accelerating research, innovations, and adoption of advanced technologies. Government agencies worldwide are increasing healthcare budgets and cancer research grants to combat the growing cancer burden, while private investors are funding biotech startups focused on CTC applications. This financial support is fostering advancements in isolation techniques, molecular assays, and liquid biopsy platforms, making diagnostics more accurate and affordable. Funding also facilitates large-scale clinical trials, validating the clinical employment of CTCs in monitoring and therapy selection. Moreover, collaborations between research institutions, hospitals, and private firms are expanding due to increased capital availability. As investments continue to rise, the CTC market is experiencing faster growth, with improved solutions reaching patients more rapidly.

GLOBAL CIRCULATING TUMOR CELLS (CTC) INDUSTRY SEGMENTATION:

Breakup by Technology:

• CTC Detection and Enrichment Method
• CTC Direct Detection Methods
• CTC Analysis

CTC detection and enrichment method dominate the market

CTC detection and enrichment method enhances the specificity, sensitivity, and efficiency of CTC isolation from blood samples. One of the notable launches is the CellSearch system, the first FDA-approved technology for CTC detection in metastatic breast cancer.

Breakup by Application:

• Clinical/Liquid Biopsy
  • Risk Assessment
  • Screening and Monitoring
• Research
  • Cancer Stem Cell and Tumorigenesis Research
  • Drug/Therapy Development

Research currently holds most of the total circulating tumor cells (CTC) market share

The introduction of cutting-edge methodologies and technologies aimed at enhancing CTC characterization, detection, and clinical application is augmenting the segment's growth.

Breakup by Product:

• Kits and Reagents
• Blood Collection Tubes
• Devices and Systems

Devices and systems hold the majority of the global circulating tumor cells (CTC) market demand

The inflating need for cancer detection and monitoring is acting as a significant growth-inducing factor. The ClearCell FX system launched a label-free, microfluidic approach that improved cell purity and viability.

Breakup by Specimen:

• Blood
• Bone Marrow
• Other Body Fluids

Blood dominates the circulating tumor cells (CTC) market outlook

The analysis of circulating tumor cells (CTCs) in the blood stimulates the capabilities and applications of this technology in oncology. For example, the ClearCell FX system gained traction, as it is a novel label-free, microfluidic technique, which enhanced the isolation process.

Breakup by End User:

• Hospital and Clinics
• Research and Academic Institutes
• Diagnostic Centres

Hospitals and clinics need enhanced patient care through more personalized and timely interventions. Research and academic institutes leverage CTC technologies to understand tumor biology, advance cancer research, and develop new therapeutic strategies. Diagnostic centers further offer early cancer detection and monitoring of treatment efficacy. As per the circulating tumor cells (CTC) market forecast report, this is acting as a significant growth-inducing factor.

Breakup by Region:

• North America
  • United States
  • Canada
• Asia-Pacific
  • China
  • Japan
  • India
  • South Korea
  • Australia
  • Indonesia
  • Others
• Europe
  • Germany
  • France
  • United Kingdom
  • Italy
  • Spain
  • Russia
  • Others
• Latin America
  • Brazil
  • Mexico
  • Others
• Middle East and Africa

North America exhibits a clear dominance in the market

The circulating tumor cells (CTC) market research report has also provided a comprehensive analysis of all the major regional markets, which include North America (the United States and Canada); Asia Pacific (China, Japan, India, South Korea, Australia, Indonesia, and others); Europe (Germany, France, the United Kingdom, Italy, Spain, Russia, and others); Latin America (Brazil, Mexico, and others); and the Middle East and Africa. According to the report, North America accounted for the largest market share.

The increasing prevalence of cancer is augmenting the market. Moreover, the escalating demand for cancer immunotherapy in the United States will continue to fuel the market in the coming years. According to the IMARC, the United States cancer immunotherapy market size is expected to exhibit a growth rate (CAGR) of approximately 10.90% during 2024-2032.

COMPETITIVE LANDSCAPE:

The market research report has provided a comprehensive analysis of the competitive landscape. Detailed profiles of all major market companies have also been provided. Some of the key players in the market include:

• BioFluidica
• Bio-Techne
• Cell Microsystems
• Creatv MicroTech Inc.
• CytoLumina
• Ikonisys Inc.
• Menarini Silicon Biosystems Inc.
• Miltenyi Biotec
• Precision Medicine Group, LLC
• Qiagen N.V.
• Rarecells, Inc.
• Stemcell Technologies
• Thermo Fisher Scientific Inc.

()

KEY QUESTIONS ANSWERED IN THIS REPORT

1. What was the size of the global Circulating Tumor Cells (CTC) market in 2025?

2. What is the expected growth rate of the global Circulating Tumor Cells (CTC) market during 2026-2034?

3. What are the key factors driving the global Circulating Tumor Cells (CTC) market?

4. What has been the impact of COVID-19 on the global Circulating Tumor Cells (CTC) market?

5. What is the breakup of the global circulating tumor cells (CTC) market based on technology?

6. What is the breakup of the global Circulating Tumor Cells (CTC) market based on the application?

7. What is the breakup of the global Circulating Tumor Cells (CTC) market based on the product?

8. What is the breakup of the global Circulating Tumor Cells (CTC) market based on the specimen?

9. What are the key regions in the global Circulating Tumor Cells (CTC) market?

10. Who are the key players/companies in the global Circulating Tumor Cells (CTC) market?

Table of Contents

1 Preface

2 Scope and Methodology

• 2.1 Objectives of the Study
• 2.2 Stakeholders
• 2.3 Data Sources
  • 2.3.1 Primary Sources
  • 2.3.2 Secondary Sources
• 2.4 Market Estimation
  • 2.4.1 Bottom-Up Approach
  • 2.4.2 Top-Down Approach
• 2.5 Forecasting Methodology

3 Executive Summary

4 Introduction

• 4.1 Overview
• 4.2 Key Industry Trends

5 Global Circulating Tumor Cells (CTC) Market

• 5.1 Market Overview
• 5.2 Market Performance
• 5.3 Impact of COVID-19
• 5.4 Market Forecast

6 Market Breakup by Technology

• 6.1 CTC Detection and Enrichment Method
  • 6.1.1 Market Trends
  • 6.1.2 Market Forecast
• 6.2 CTC Direct Detection Methods
  • 6.2.1 Market Trends
  • 6.2.2 Market Forecast
• 6.3 CTC Analysis
  • 6.3.1 Market Trends
  • 6.3.2 Market Forecast

7 Market Breakup by Application

• 7.1 Clinical/Liquid Biopsy
  • 7.1.1 Market Trends
  • 7.1.2 Key Segments
    • 7.1.2.1 Risk Assessment
    • 7.1.2.2 Screening and Monitoring
  • 7.1.3 Market Forecast
• 7.2 Research
  • 7.2.1 Market Trends
  • 7.2.2 Key Segments
    • 7.2.2.1 Cancer Stem Cell and Tumorigenesis Research
    • 7.2.2.2 Drug/Therapy Development
  • 7.2.3 Market Forecast

8 Market Breakup by Product

• 8.1 Kits and Reagents
  • 8.1.1 Market Trends
  • 8.1.2 Market Forecast
• 8.2 Blood Collection Tubes
  • 8.2.1 Market Trends
  • 8.2.2 Market Forecast
• 8.3 Devices or Systems
  • 8.3.1 Market Trends
  • 8.3.2 Market Forecast

9 Market Breakup by Specimen

• 9.1 Blood
  • 9.1.1 Market Trends
  • 9.1.2 Market Forecast
• 9.2 Bone Marrow
  • 9.2.1 Market Trends
  • 9.2.2 Market Forecast
• 9.3 Other Body Fluids
  • 9.3.1 Market Trends
  • 9.3.2 Market Forecast

10 Market Breakup by End User

• 10.1 Hospital and Clinics
  • 10.1.1 Market Trends
  • 10.1.2 Market Forecast
• 10.2 Research and Academic Institutes
  • 10.2.1 Market Trends
  • 10.2.2 Market Forecast
• 10.3 Diagnostic Centres
  • 10.3.1 Market Trends
  • 10.3.2 Market Forecast

11 Market Breakup by Region

• 11.1 North America
  • 11.1.1 United States
    • 11.1.1.1 Market Trends
    • 11.1.1.2 Market Forecast
  • 11.1.2 Canada
    • 11.1.2.1 Market Trends
    • 11.1.2.2 Market Forecast
• 11.2 Asia-Pacific
  • 11.2.1 China
    • 11.2.1.1 Market Trends
    • 11.2.1.2 Market Forecast
  • 11.2.2 Japan
    • 11.2.2.1 Market Trends
    • 11.2.2.2 Market Forecast
  • 11.2.3 India
    • 11.2.3.1 Market Trends
    • 11.2.3.2 Market Forecast
  • 11.2.4 South Korea
    • 11.2.4.1 Market Trends
    • 11.2.4.2 Market Forecast
  • 11.2.5 Australia
    • 11.2.5.1 Market Trends
    • 11.2.5.2 Market Forecast
  • 11.2.6 Indonesia
    • 11.2.6.1 Market Trends
    • 11.2.6.2 Market Forecast
  • 11.2.7 Others
    • 11.2.7.1 Market Trends
    • 11.2.7.2 Market Forecast
• 11.3 Europe
  • 11.3.1 Germany
    • 11.3.1.1 Market Trends
    • 11.3.1.2 Market Forecast
  • 11.3.2 France
    • 11.3.2.1 Market Trends
    • 11.3.2.2 Market Forecast
  • 11.3.3 United Kingdom
    • 11.3.3.1 Market Trends
    • 11.3.3.2 Market Forecast
  • 11.3.4 Italy
    • 11.3.4.1 Market Trends
    • 11.3.4.2 Market Forecast
  • 11.3.5 Spain
    • 11.3.5.1 Market Trends
    • 11.3.5.2 Market Forecast
  • 11.3.6 Russia
    • 11.3.6.1 Market Trends
    • 11.3.6.2 Market Forecast
  • 11.3.7 Others
    • 11.3.7.1 Market Trends
    • 11.3.7.2 Market Forecast
• 11.4 Latin America
  • 11.4.1 Brazil
    • 11.4.1.1 Market Trends
    • 11.4.1.2 Market Forecast
  • 11.4.2 Mexico
    • 11.4.2.1 Market Trends
    • 11.4.2.2 Market Forecast
  • 11.4.3 Others
    • 11.4.3.1 Market Trends
    • 11.4.3.2 Market Forecast
• 11.5 Middle East and Africa
  • 11.5.1 Market Trends
  • 11.5.2 Market Breakup by Country
  • 11.5.3 Market Forecast

12 SWOT Analysis

• 12.1 Overview
• 12.2 Strengths
• 12.3 Weaknesses
• 12.4 Opportunities
• 12.5 Threats

13 Value Chain Analysis

14 Porters Five Forces Analysis

• 14.1 Overview
• 14.2 Bargaining Power of Buyers
• 14.3 Bargaining Power of Suppliers
• 14.4 Degree of Competition
• 14.5 Threat of New Entrants
• 14.6 Threat of Substitutes

15 Price Analysis

16 Competitive Landscape

• 16.1 Market Structure
• 16.2 Key Players
• 16.3 Profiles of Key Players
  • 16.3.1 BioFluidica
    • 16.3.1.1 Company Overview
    • 16.3.1.2 Product Portfolio
  • 16.3.2 Bio-Techne
    • 16.3.2.1 Company Overview
    • 16.3.2.2 Product Portfolio
  • 16.3.3 Cell Microsystems
    • 16.3.3.1 Company Overview
    • 16.3.3.2 Product Portfolio
  • 16.3.4 Creatv MicroTech Inc.
    • 16.3.4.1 Company Overview
    • 16.3.4.2 Product Portfolio
  • 16.3.5 CytoLumina
    • 16.3.5.1 Company Overview
    • 16.3.5.2 Product Portfolio
  • 16.3.6 Ikonisys Inc.
    • 16.3.6.1 Company Overview
    • 16.3.6.2 Product Portfolio
  • 16.3.7 Menarini Silicon Biosystems Inc.
    • 16.3.7.1 Company Overview
    • 16.3.7.2 Product Portfolio
  • 16.3.8 Miltenyi Biotec
    • 16.3.8.1 Company Overview
    • 16.3.8.2 Product Portfolio
  • 16.3.9 Precision Medicine Group, LLC
    • 16.3.9.1 Company Overview
    • 16.3.9.2 Product Portfolio
  • 16.3.10 Qiagen N.V.
    • 16.3.10.1 Company Overview
    • 16.3.10.2 Product Portfolio
  • 16.3.11 Rarecells, Inc.
    • 16.3.11.1 Company Overview
    • 16.3.11.2 Product Portfolio
  • 16.3.12 Stemcell Technologies
    • 16.3.12.1 Company Overview
    • 16.3.12.2 Product Portfolio
  • 16.3.13 Thermo Fisher Scientific Inc.
    • 16.3.13.1 Company Overview
    • 16.3.13.2 Product Portfolio